Momenta Pharmaceuticals, Inc.

675 West Kendall Street
Cambridge
Massachusetts
02142
United States

Tel: 617-491-9700
Fax: 617-621-0431

Email: info@momentapharma.com

Show jobs for this employer

About Momenta Pharmaceuticals, Inc.


Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of complex generics, biosimilars and novel drugs designed to address a variety of medical needs.

In April 2015, Momenta announced the FDA approval of once daily Glatopa™ (glatiramer acetate injection), a fully substitutable generic version of Copaxone® 20 mg/mL. Glatopa was developed under a collaboration agreement between Momenta and Sandoz and is the second complex generic developed by Momenta to receive FDA approval.

In July 2010, Momenta announced the FDA approval of our first drug, Enoxaparin Sodium Injection developed in collaboration with Sandoz.

326 articles with Momenta Pharmaceuticals, Inc.